Skip to main content

Glioblastoma Multiforme News

Related terms: GBM

Moderate-to-Severe TBI Linked to Malignant Brain Tumor Risk

FRIDAY, Sept. 5, 2025 – A history of moderate-to-severe traumatic brain injury (TBI) is associated with an increased risk for developing malignant brain tumors, according to a study published online...

Study Offers Comprehensive Evaluation of Survival Parameters for Pediatric CNS Tumors

MONDAY, Aug. 4, 2025 – The survival probabilities of pediatric central nervous system (CNS) tumors in Europe have been explored in a study published in the August issue of The Lancet Oncology....

Brain Tumors In Firefighters Linked To Flame Retardant Chemical

TUESDAY, March 11, 2025 – Firefighters might face a higher risk of brain cancers caused by exposure to chemicals in fire extinguishers, a new small-scale study says. Veteran firefighters appear to...

Rapid Gene Test Aids Brain Cancer Surgery

WEDNESDAY, Feb. 26, 2025 – A rapid experimental genetic test can help guide the hands of surgeons as they delicately remove tumors from patients with brain cancer, new research suggests. The test...

Hormone Therapy Doesn't Increase Women's Risk of Brain Tumors

TUESDAY, Jan. 21, 2025 – Hormone replacement therapy to ease menopause symptoms doesn’t increase a woman’s risk of brain tumors. Researchers found no link between hormone therapy and gliomas, the mos...

AI Helps Spot Brain Tumor Tissue Surgeons Miss

WEDNESDAY, Nov. 13, 2024 – A newly developed AI program can help doctors detect and potentially remove brain cancer that might otherwise be missed during surgery, a new study demonstrates. The AI,...

Anatomic Changes Can Be Seen With MRI-Linac for Glioblastoma Patients

FRIDAY, Oct. 11, 2024 – For patients with glioblastoma imaged daily with magnetic resonance imaging (MRI)-linear accelerator (linac) throughout the chemoradiation therapy course, anatomic changes...

FDA Approves Vegzelma (bevacizumab-adcd), a Biosimilar to Avastin

Vegzelma is Celltrion’s third oncology biosimilar to receive approval from the U.S. FDA Vegzelma offers U.S. patients living with multiple types of cancer a new, safe, and effective treatment option ...

FDA Approves Alymsys (bevacizumab-maly), a Biosimilar to Avastin

BRIDGEWATER, N.J.--(BUSINESS WIRE) April 13, 2022 --Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved ...

FDA Approves Zirabev (bevacizumab-bvzr), a Biosimilar to Avastin

Friday, June 28, 2019 - Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration(FDA) has approved Zirabev (bevacizumab-bvzr), a biosimilar to...

FDA Grants Genentech’s Avastin Full Approval for Most Aggressive Form of Brain Cancer

South San Francisco, CA – December 5, 2017 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted full...

FDA Approves Mvasi (bevacizumab-awwb), a Biosimilar to Avastin

September 14, 2017 – The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of cancer. Mvasi is...

FDA Medwatch Alert: BiCNU (carmustine for injection): FDA Alert - Counterfeit Product Discovered in Some Foreign Countries

ISSUE: FDA is informing health care professionals that a counterfeit version of the FDA approved cancer drug, BiCNU (carmustine for injection) 100 mg, has been detected in some foreign countries....

Ask a question

To post your own question to our community, sign in or create an account.